stephen silberstein, md, director, jefferson university headache center.
.
.
.
.
the school in yarmouth that year had a low opt-out rate � 2 percent, the superintendent said � so there was a cap on the amount of disruption an illness could cause.
.
.
.
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
.
.
.